Kodiak Sciences (KOD)
Develops intravitreal biologics for retinal vascular and inflammatory diseases.
Algert Global LLC Purchases 38,546 Shares of Kodiak Sciences Inc. $KOD
Algert Global LLC increased its stake in shares of Kodiak Sciences Inc. (NASDAQ: KOD) by 26.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 186,476 shares of the company's stock after purchasing an additional 38,546 shares during the quarter.
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026.
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.
Kodiak Sciences (NASDAQ:KOD) Shares Up 6.6% – What’s Next?
Shares of Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shot up 6.6% on Friday. The company traded as high as $43.94 and last traded at $43.9590. Approximately 68,404 shares changed hands during trading, a decline of 92% from the average session volume of 900,653 shares. The stock had previously closed at $41.25. Wall
Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage
Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopathy and upcoming pivotal data for Zenkuda, KSI-501, and KSI-101 underpin a bullish outlook. KOD's current $169.5M cash position supports near-term catalysts, but additional capital will be needed for commercialization and late-stage development.
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.
Kodiak Sciences: Road To $120
Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fueled by robust Phase 3 GLOW2 results for Zenkuda (tarcocimab), an experimental treatment aimed at retinal vascular disorders.
Kodiak Sciences (NASDAQ:KOD) Reaches New 52-Week High – Time to Buy?
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shares hit a new 52-week high during trading on Thursday. The company traded as high as $36.84 and last traded at $36.0160, with a volume of 3075248 shares. The stock had previously closed at $22.75. More Kodiak Sciences News Here are the key news stories impacting
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate
Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients.
Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?
Investors appear to be responding to both the strength of the data and the possibility of a faster path toward a biologics license application, or BLA. Here's what investors need to know.
Kodiak Sciences shares surge after eye drug succeeds in late-stage study
Shares of drug developer Kodiak Sciences jumped 52% before the bell on Thursday after its experimental drug met the main goal in a late-stage study in patients with diabetes-related eye damage.
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Kodiak Sciences Inc. (NASDAQ:KOD) Receives $28.29 Consensus Target Price from Brokerages
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company.